Masitinib is safe and effective for the treatment of canine mast cell tumors.

@article{Hahn2008MasitinibIS,
  title={Masitinib is safe and effective for the treatment of canine mast cell tumors.},
  author={Kevin A. Hahn and Gregory K. Ogilvie and T Rusk and Patrick Devauchelle and Amy K LeBlanc and Alfred M. Legendre and Barbara E. Powers and Phillip S. Leventhal and Jean Pierre Kinet and Fabienne Palm{\'e}rini and Pascal Dubreuil and Alain Moussy and Olivier Hermine},
  journal={Journal of veterinary internal medicine},
  year={2008},
  volume={22 6},
  pages={
          1301-9
        }
}
BACKGROUND Activation of the KIT receptor tyrosine kinase is associated with the development of canine mast cell tumors (MCT). HYPOTHESIS/OBJECTIVE To evaluate the efficacy of masitinib, a potent and selective inhibitor of KIT, in the treatment of canine MCT. ANIMALS Two hundred and two client-owned dogs with nonmetastatic recurrent or nonresectable grade II or III MCT. METHODS Double-blind, randomized, placebo-controlled phase III clinical trial. Dogs were administered masitinib (12.5 mg… 
Masitinib mesylate for metastatic and non-resectable canine cutaneous mast cell tumours.
TLDR
Responsibility to masitinib, not tumour grade, stage or location, was the most significant prognostic factor for survival in dogs with MCTs.
Safety of masitinib mesylate in healthy cats.
TLDR
Masitinib mesylate was tolerated in the majority of cats, and long-term administration and pharmacokinetic studies are needed to further assess the use of masit inib in cats.
Clinical response of masitinib mesylate in the treatment of canine macroscopic mast cell tumours.
TLDR
Masitinib appears to be a well-tolerated and effective drug against macroscopic mast cell tumours in the dog.
Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro
TLDR
These results provide rationale for further investigation into the use of TKIs, possibly in combination with doxorubicin, as treatment options for COF.
Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells
TLDR
It is found that masitinib causes dose-time dependent OSA cell death in vitro through initiation of caspase-mediated apoptosis, which supports future OSA clinical trials.
Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.
TLDR
Masitinib proved to be an effective and mostly well-tolerated treatment of CAD, including severe and refractory cases, with medically manageable adverse effects.
Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.
TLDR
Control of disease at 6 months, but not best response at 6 weeks, was predictive of long-term survival in dogs treated with masitinib, which suggested that short-term response may be irrelevant for assessing clinical efficacy of tyrosine kinase inhibitors for treatment of MCTs.
Clinical, histological, immunohistochemical and genetic factors associated with measurable response of high-risk canine mast cell tumours to tyrosine kinase inhibitors
TLDR
Initial response to TKIs appears to be the most reliable prognostic factor for survival duration, and internal tandem duplications in exon 11 of the c-kit gene were identified in 6/24 cases.
Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
Pharmacokinetics of masitinib in cats
TLDR
The results of a preliminary pharmacokinetic study of masitinib in cats showed a good bioavailability of ~60% in both sexes, and it is proposed that an oral dose of 10–15 mg/kg masit inib is appropriate to achieve adequate plasma concentrations.
...
...

References

SHOWING 1-10 OF 27 REFERENCES
Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
  • C. London, A. Hannah, J. Cherrington
  • Medicine, Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
TLDR
This study provides the first evidence that p.o. administered kinase inhibitors can exhibit activity against a variety of spontaneous malignancies in dogs, and it is likely that such agents will demonstrate comparable antineoplastic activity in people.
Treatment of canine mast cell tumors with CCNU (lomustine).
TLDR
CCNU should be considered an active agent in the treatment of MCT in dogs and the acute dose-limiting toxicity was neutropenia 7 days after administration of CCNU.
Prednisone and vinblastine chemotherapy for canine mast cell tumor--41 cases (1992-1997).
TLDR
Forty-one dogs with mast cell tumors were treated with oral prednisone and injectable vinblastine, both in the adjuvant setting and in dogs with gross disease, with apparent improvement over historical survival data employing surgery alone.
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors.
  • S. Eckhardt, J. Rizzo, E. Rowinsky
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1999
TLDR
Although further dose escalation was precluded by infusate volume constraints, this SU101 dose schedule resulted in the achievement and maintenance of substantial plasma concentrations of the major metabolite, SU0020, for the entire treatment period.
Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
  • N. Pryer, Leslie B. Lee, C. London
  • Biology, Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
TLDR
SU11654 treatment at the efficacious dose results in inhibition of KIT phosphorylation in canine MCTs and correlates target inhibition with mutational status of the c-kit juxtamembrane domain and SU11654 plasma concentration.
A prospective study of radiation therapy for the treatment of grade 2 mast cell tumors in 32 dogs.
TLDR
Radiation therapy appears to be an effective treatment for dogs with grade 2, stage 0 MCT and was limited to acute cutaneous reactions in all cases.
Mast cell tumors in the dog.
  • C. London, B. Séguin
  • Medicine
    The Veterinary clinics of North America. Small animal practice
  • 2003
...
...